There is more and more evidence in the literature indicating the role of ApoA-I in the pathogenesis and severity of lung disease: ApoA-I mimetic peptides have been found to be useful in the treatment of lung diseases such as viral pneumonia [63], pulmonary hypertension [64], asthma [65], and acute respiratory distress syndrome [66]. Here, APOA1 is linked to acute respiratory distress syndrome.